OVARIAN CANCER

(1), ovarian cancer-chemotherapy drug commonly used drug <BR> melphalan (PAM) 0.2 ^ / ㎏ d, oral, 4 ~ for a course on the 5th, rest four to six weeks after duplication. Thiotepa (161-169) 10 ^ / times, intramuscular or intravenous injection, used five times, every other day to once a total of 300 ~ 500 days for an induction course. 6 to 8 weeks under the condition repeat. Cyclophosphamide (CTX) 50 ~ 100 ^ / day, oral, 7 ~ 10 Tianyi treatment, two weeks after duplication. Or 400 ^ / day, intravenous, oral to four days. Adriamycin (ADM) 50 ~ 70 ^ / ㎡, intravenous injection. Every three weeks.
(2), and malignant ovarian tumor joint chemical treatment of ovarian cancer chemotherapy are better response. In recent years the chemical treatment of tumors faster progress in the treatment of ovarian cancer Habitat has an important place to improve the treatment of ovarian cancer play a positive role as a surgical adjuvant therapy, commonly used in the preoperative, intraoperative and postoperative, but often require a longer period of intermittent medication, and the human body toxicity also sometimes larger. In most cases, it is difficult to ovarian cancer surgery primary tumor and metastasis consider chemical treatment based treatment.

Tags: body, cancer, cases, chemotherapy, days, drug, eat, injection, intravenous, malignant, metastasis, ovarian, positive, response, surgery, surgical, therapy, time, toxicity, treatment, tumor, tumors

Treatment of ovarian cancer is still surgery and chemotherapy, although postoperative adjuvant systemic chemotherapy has been the effect certainly, but in some patients because of poor health and not systemic tolerance of the boil, and in some patients for fear of adverse reactions of chemotherapy automatically abandon further treatment, which greatly affects the quality of life and survival rate , an increase of ovarian cancer recurrence possible. The TCM adjuvant treatment of patients with chemotherapy can improve and the tolerance level of immunity and, therefore, Chinese medicine treatment of ovarian cancer has been more and more attention.

Tags: age, bleeding, cancer, cause, chemotherapy, cisplatin, clinical, drug, drugs, eat, ert, gene, injection, intravenous, knowledge, life, ovarian, patients, poor, prognosis, quality, rate, second, surgery, survival, symptoms, therapy, time, treatment, tumor, tumors

Daqing City in Heilongjiang hospital recently adopted a new therapy combining traditional Chinese and western medicine, ultrasound-guided puncture, self-developed "Gallnut hardening agent" for the treatment of ovarian cysts, to date a total of more than 400 patients is associated disarmed.

"Gallnut hardening agent" by gallnut, brucea javanica, Yuan Hu, the group formed by the injection of a scientific process. Modern pharmacology studies confirmed: Gallnut obvious convergence, enable protein containing tannic acid precipitation; Brucea javanica contained Brucea javanica oil, could undermine something superfluous cell nucleus; Yuan Hu good analgesic effect.

Tags: age, cell, cells, cyst, cysts, drug, eat, group, injection, ovarian, patients, protein, therapy, treatment

Ovarian cancer is the worst prognosis of gynecologic tumors. Patients with advanced epithelial ovarian cancer five-year survival rates generally below 30%, mainly in patients with relapsing most (about 75%), relapse after chemotherapy to poor results.

For the treatment of recurrent ovarian cancer chemotherapy drugs many, no less than 10 species, but only clinical remission rate of 20% to 30%, no progress median survival time (PFS) for 2 to 6 months, the median overall survival (OS) for six to 12 months. Therefore, to improve the efficacy of chemotherapy drugs delay, but the development of new drugs is very difficult, efficient use of existing drugs is an effective way to <BR>.

Tags: cancer, cases, chemotherapy, cisplatin, clinical, drug, drugs, early, eat, exploration, gene, group, method, ovarian, p53, paclitaxel, patients, pmtc, poor, positive, prognosis, rate, second, study, survival, taxol, therapy, time, treatment, tumor, tumors

Researchers reported that the joint use of both cisplatin and paclitaxel chemotherapy drug for ovarian cancer achieved better clinical remission rate and a higher survival rate, this new program has become advanced ovarian cancer patients with standard treatment programs.

From the European Organization for Cancer Research and Treatment of Dr Piccart, a group of researchers across the Atlantic to the two large-scale clinical trials group that cisplatin and paclitaxel (TP) both chemotherapy treatment of advanced ovarian cancer with significant advantages.

Tags: age, anti, cancer, chemotherapy, cisplatin, clinical, drug, eat, grams, group, history, ovarian, paclitaxel, patients, rate, study, survival, therapy, treatment, tumor, tumors

A large number of pre-clinical data and the right abdominal anatomy, physiology and biology of ovarian cancer have suggested that understanding, abdominal local cytotoxic drug treatment for ovarian cancer is very reasonable. Intraperitoneal chemotherapy Phase I clinical trial confirmed the chemotherapy drugs and intraperitoneal chemotherapy safety of the technology itself, confirmed the intraperitoneal chemotherapy in the pharmacokinetic advantages.

In some multi-center Phase II clinical trials, surgical results confirmed that about 20% to 40% of second-tier category to cisplatin-based chemotherapy in patients with celiac complete remission, the part of the residual cancer patients <0.5 cm before  acceptable to platinum-based chemotherapy effective systemic System .

Tags: abdominal, administration, age, cancer, carboplatin, cause, chemotherapy, cisplatin, clinical, days, drug, drugs, eat, group, incidence, infusion, injection, intraperitoneal, intravenous, ovarian, paclitaxel, pain, patients, rate, reduce, residual, second, study, surgical, survival, taxol, therapy, time, toxicity, treatment, tumor

Patients with malignant ovarian tumor when treatment is late (> Phase II), ovarian cancer is the surgical treatment called tumor or cytoreductive surgery or large resection.
Surgery is to do everything possible to the original tumor resection and can see the pots, peritoneal metastasis, so that each region of residual lesion diameter of less than 2.0 cm to 1.5 cm. Intraoperative from ascites fluid or cells for blood screening. Because ovarian and uterine cancer often, the annex or visco-invasion, peritoneal and keep pots, it is more of "carpet-volume" or "dumplings", from extraperitoneal space elements from the peritoneal wall, bladder and pelvic floor serous peritoneal, along with the uterus and pelvic peritoneum block tumor resection. The pots have peritoneal metastasis tissues or organs should be possible to complete resection or partial resection, resection of the omentum, some intestinal resection, resection of the bladder or ureter shifting values. The removal of the tumor as possible aim is to enhance postoperative radiotherapy and chemotherapy effect. The merger of ovarian cancer ascites, regardless of whether all resection are advised to intraperitoneal indwelling catheter for intraperitoneal injection of anti-cancer drugs. Anti-cancer drugs or radioisotopes for preparation also can be injected directly unresectable tumors.
Surgery can not decide in its benign and malignant ovarian tumor resection specimens should be admitted or contralateral ovarian tissue frozen tablets sent for histopathologic examination. There is no such conditions, generally after the contralateral normal ovarian As can be temporarily retained, pathological specimens were sent checks to clear in nature, and close observation. The previous suspected metastatic ovarian tumor and failed to find its source, should be in operation in detail in the original exploration of abdominal lesions, after further treatment for reference.

Tags: abdominal, annex, anti, benign, blood, cancer, cause, cell, cells, chemotherapy, drug, drugs, eat, examination, exploration, gene, injection, intraperitoneal, malignant, metastasis, metastatic, ovarian, patients, pelvic, radiotherapy, resection, residual, screening, surgery, surgical, therapy, treatment, tumor, tumors, uterine

Ovarian cancer

Tags: age, annex, blood, body, cancer, cases, cell, cells, chemotherapy, clinical, cyst, cystic, diagnosis, drug, drugs, early, eat, examination, fat, mass, method, ovarian, pain, patients, pelvic, poor, prognosis, reduce, resection, study, surgical, symptoms, therapy, time, toxicity, treatment, tumor, tumors, women

Epithelial ovarian cancer in the United States is a relatively rare in Gynecologic Oncology, 2004, there were approximately 25,580 cases of new onset patients, 16,090 cases patients died. The majority of patients with advanced cancer, treatment for surgical resection and postoperative to platinum-based chemotherapy. During the past 10 years, chemotherapy improved survival rates improve, and recurrent tumor treatment more effective. In addition, the genetic risk factors for making in-depth understanding of the prevention strategy to become individualized approach to bilateral tubal women - ovarian surgery. This report summarized the clinical characteristics of epithelial ovarian, after reports focus on the treatment of the latest developments.

Tags: age, brca1, breast, cancer, carcinoma, cases, cause, chemotherapy, clinical, diagnosis, drug, drugs, early, eat, ert, estrogen, examination, family, gene, group, groups, history, incidence, increased, life, malignant, mutation, ovarian, ovary, patients, pelvic, preventive, protein, rate, reduce, resection, risk, screening, second, study, surface, surgery, surgical, survival, syndrome, therapy, time, treatment, tumor, usually, women

One, paclitaxel and cisplatin in the treatment of advanced ovarian cancer care <BR> <BR> 1990s Taxol is more of the treatment of advanced ovarian cancer drug effective, and its unique mechanism is a new type of anti-tubulin role of antitumor drugs. Cisplatin for inorganic platinum metal complex, the cell cycle-specific drug, can inhibit DNA synthesis, combined with their synergies to enhance the effectiveness of [1]. In Division I from July 1996 to July 1998 to 15 cases of advanced ovarian cancer patients with Taxol and cisplatin in the treatment of satisfactory results.

One, information and Methods

Tags: administration, age, anti, blood, body, cancer, care, cases, cause, cell, cells, chemotherapy, cisplatin, clinical, confidence, days, diet, dose, drug, drugs, eat, ert, estrogen, family, fat, gene, group, growth, incidence, infusion, injection, intravenous, life, mass, metastasis, method, ovarian, paclitaxel, pain, patients, physical, poor, positive, psychological, quality, rate, reduce, response, skin, surface, surgery, survival, symptoms, taxol, therapy, time, toxicity, treatment, tumor, tumors, women